Dr Jitendra Singh on PCOS renamed PMOS: Why new name matters for women’s health
New Delhi: For millions of women who have spent years being told they have “polycystic ovaries”, a seemingly small change in medical terminology could signal a much bigger shift in how the condition is understood. Union Minister Dr Jitendra Singh has highlighted the renaming of Polycystic Ovary Syndrome (PCOS) as Polyendocrine Metabolic Ovarian Syndrome (PMOS), bringing renewed attention in India to a global medical consensus that aims to move the focus beyond the ovaries and towards the disorder’s wider hormonal and metabolic effects.
Why PCOS was considered misleading name
The term “polycystic” has long created the impression that ovarian cysts are the defining feature of the disorder. Medical experts say this is misleading. The ovarian appearance associated with PCOS often represents numerous small follicles rather than conventional pathological cysts, and not every affected woman has this ovarian appearance.
More importantly, PCOS is a heterogeneous, multisystem condition involving hormonal disturbances and metabolic dysfunction, with consequences that can extend beyond reproduction. The global consensus paper published in The Lancet says the old terminology contributed to misunderstanding, delayed diagnosis, fragmented care and stigma.
What does PMOS mean
The new name, Polyendocrine Metabolic Ovarian Syndrome, deliberately broadens the lens.
“Polyendocrine” acknowledges the involvement of multiple hormonal pathways. “Metabolic” puts conditions such as insulin resistance and related metabolic abnormalities firmly within the picture, while “ovarian” retains the reproductive dimension of the syndrome.
According to the Endocrine Society, PMOS affects roughly one in eight women, or more than 170 million women worldwide. Its manifestations can include irregular menstrual cycles, androgen-related symptoms, fertility difficulties, weight and metabolic problems, skin changes and mental-health impacts.
14-Year global effort behind rename
This is not an overnight rebranding exercise. The change followed an international consensus process spanning about 14 years, involving patients, clinicians, researchers and professional organisations across different regions.
The Lancet paper reports participation from 56 leading academic, clinical and patient organisations and describes a structured, multistep process designed to build international agreement around the new terminology.
The consensus was led by Professor Helena Teede and involved experts from endocrinology, reproductive medicine and related fields. The stated objective was to ensure that the name itself communicates the complexity of the condition rather than reinforcing an ovarian-only interpretation.
Does PMOS change diagnosis or treatment
No – not immediately. This distinction is crucial.
The renaming does not mean that women suddenly have a new disease, nor does it automatically change established diagnostic criteria or treatments. The condition formerly called PCOS remains the same clinical disorder; PMOS is intended to describe it more accurately.
The significance lies primarily in how doctors, patients, researchers and health systems conceptualise the condition. The consensus process envisages implementation across terminology, education, research, policy and healthcare systems rather than an overnight replacement of every existing medical record or guideline.
Why the change matters for India
For India, where PCOS is already a major women’s-health concern, the shift could encourage a more integrated approach to care.
Instead of treating irregular periods, infertility, acne, unwanted hair growth or weight-related concerns as isolated problems, PMOS reinforces the need to consider the wider endocrine and metabolic picture. Research published in 2026 has also highlighted the relationship between the condition and metabolic risks among South Asian patients.
Dr Jitendra Singh’s post is therefore significant because it brings the international medical development into India’s public conversation around women’s health. The message is not that PCOS has suddenly become a different disease, but that medicine’s understanding of it has evolved.
The name has changed. The condition has not. What may change, however, is the way the world see, and ultimately treats, women living with it.